Anti-müllerian hormone deficiency in females with Fanconi Anemia

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 5, 2014, Pages 1608-1614

  Sklavos, Martha M ^a   Giri, Neelam ^b   Stratton, Pamela ^c   Alter, Blanche P ^b   Pinto, Ligia A ^a  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUELLERIAN INHIBITING FACTOR;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FANCONI ANEMIA; FEMALE; HORMONAL REGULATION; HORMONE DEFICIENCY; HORMONE DETERMINATION; HUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTI-MULLERIAN HORMONE; BIOLOGICAL MARKERS; CHILD; CROSS-SECTIONAL STUDIES; FANCONI ANEMIA; FEMALE; HUMANS; PRIMARY OVARIAN INSUFFICIENCY;

EID: 84899931169     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3559     Document Type: Article

References (31)

1. Shimamura A, Alter BP. Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev. 2010;24(3): 101-122.
2. Rosenb erg PS, Tamary H, Alter BP. How high are carrier frequencies of rare recessive syndromes Contemporary estimates for Fanconi anemia in the United States and Israel. Am J Med Genet A. 2011;155A(8):1877-1883.
3. Titus S, Li F, Stobezki R, et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med. 2013;5(172):172ra21.
4. va n de Vrugt HJ, Cheng NC, de Vries Y, et al. Cloning and characterization of murine Fanconi anemia group A gene: Fanca protein is expressed in lymphoid tissues, testis, and ovary. Mamm Genome. 2000;11(4):326-331.
5. Hampl R, Snajderova M, Mardesic T. Antimullerian hormone (AMH) not only a marker for prediction of ovarian reserve. Physiol Res. 2011;60(2):217-223.
6. Nelson SM. Bioma rkers of ovarian response: current and future applications. Fertil Steril. 2013;99(4):963-969.
7. Fleming R Kelsey TW Anderson RA Wallace WH Nelson SM. Interpreting human follicular recr uitment and antimullerian hormone concentrations throughout life Fertil Steril. 2012;98(5)1097-1102.
8. te Velde ER, Pearson PL. The variability of female reproductive ageing. Hum Reprod Update. 2002;8(2):141-154.
9. Wallace WH, Kelsey TW. Human ovarian reserve from conception to the menopause. PLoS One. 2010;5(1):e8772.
10. Giri N, Batista DL, Alter BP, Stratakis CA. Endocrine abnormalities in patients with Fanconi anemia. J Clin Endocrinol Metab. 2007; 92(7):2624-2631.
11. Welt CK. Pri mary ovarian insufficiency: a more accurate term for premature ovarian failure. Clin Endocrinol (Oxf). 2008;68(4):499-509.
12. Nelson LM. Clinical practice. Primary ovarian insufficiency.NEngl J Med. 2009;360(6):606-614.
13. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop-10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012;97(4):1159-1168.
14. Kunt C, Ozaksit G, Keskin Kurt R, et al. Anti-Mullerian hormone is a better marker than inhibin B, follicle stimulating hormone, estradiol or antral follicle count in predicting the outcome of in vitro fertilization. Arch Gynecol Obstet. 2011;283(6):1415-1421.
15. Kallio S, Aittomaki K, Piltonen T, et al. Anti-Mullerian hormone as a p redictor of follicular reserve in ovarian insufficiency: special emphasis on FSH-resistant ovaries. Hum Reprod. 2012;27(3):854-860.
16. Visser JA, Schipper I, Laven JS, Themmen AP. Anti-Mullerian hormone: an ovarian reserve marker in primary ovarian insufficiency. Nat Rev Endocrinol. 2012;8(6):331-341.
17. Alter BP, Giri N, Savage SA, et al. Malignancies and survival patterns in the Na tional Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol. 2010;150(2):179-188.
18. Lo Ten Foe JR, Kwee ML, Rooimans MA, et al. Somatic mosaicism in Fanconi anemia: molecular basis and clinical significance. Eur J Hum Genet. 1997;5(3):137-148.
19. Wallace AM, Faye SA, Fleming R, Nelson SM. A multicentre evaluation of the new Beckman Coulter anti-Mu llerian hormone immunoassay (AMH Gen II). Ann Clin Biochem. 2011;48(Pt 4):370-373.
20. Sun SS, Schubert CM, Chumlea WC, et al. National estimates of the timing of sexual maturation and racial di fferences among US children. Pediatrics. 2002;110(5):911-919.
21. Nabhan SK, Bitencourt MA, Duval M, et al. Fertility recovery and pregnancy after allogeneic hematopoietic stem cell transpla ntation in Fanconi anemia patients. Haematologica. 2010;95(10):1783-1787.
22. Alter BP, Frissora CL, Halperin DS, et al. Fanconi's anaemia and pregnancy. Br J Haematol. 1991;77(3):410-418.
23. Wang SS, Bratti MC, Rodriguez AC, et al. Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J Infect Dis. 2009; 199(1):20-30.
24. Ghosh A, Ghosh S, Maiti GP, et al. Association of FANCC and PTCH1 with the development of early dysplastic lesions of the head and neck. Ann Surg Oncol. 2012;19(suppl 3):S528-S538 .
25. MacLaughlin DT, Donahoe PK. Mullerian inhibiting substance/anti-Mullerian hormone: a potential therapeutic agent for human ovarian and other cancers. Future Oncol. 2010;6(3):391-405.
26. Brinton LA, Westhoff CL, Scoccia B, et al. Causes of infertility as predictors of subsequent cancer risk. Epidemiology. 2005;16(4): 500-507.
27. Donahoe PK, Clarke T, T eixeira J, Maheswaran S, MacLaughlin DT. Enhanced purification and production of Mullerian inhibiting substance for therapeutic applications. Mol Cell Endocrinol. 2003; 211(1-2):37-42.
28. Burger HG Hale GE Robertson DM Dennerstein L. A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women's Midlife Health Project Hum Reprod Update. 2007 13(6) 559-565.
29. La Marca A, Stabile G, Artenisio AC, Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle.HumReprod. 2006;21(12):3103-3107.
30. Streuli I, Fraisse T, Pillet C, Ibecheole V, Bischof P, de Ziegler D. Serum antimullerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril. 2008;90(2):395-400.
31. Hagen CP, Aksglaede L, Sorensen K, et al. Individual serum levels of anti-Mullerian hormone in healthy girls persist through childhood and adolescence: a longitudinal cohort study. Hum Reprod. 2012; 27(3):861-866.